---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-019462"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:14:39.141942+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix reports FY2024 revenue $63.7M, net loss $(193.5)M; updates AXPAXLI registrational program

## Summary
- Q4 2024 revenue $17.1M (+15.4% YoY); FY2024 revenue $63.7M (+9.0% YoY). Net loss $(193.5)M for FY2024 vs $(80.7)M in FY2023.
- Cash balance $392.1M as of Dec 31, 2024; expected to fund operations into 2028; no plans to raise additional capital in 2025.
- SOL-1 Phase 3 wet AMD trial amended to include re-dosing at Weeks 52 and 76; Week 36 primary endpoint data expected in 1Q 2026.
- SOL-R trial size reduced from 825 to 555 subjects due to re-dosing inclusion in SOL-1; non-inferiority margin -4.5 letters BCVA vs aflibercept.
- FDA feedback on AXPAXLI clinical trial design for NPDR and DME anticipated in 1H 2025.

## SEC filing metadata
- accession: 0001104659-25-019462
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/0001104659-25-019462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/tm258051d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-019462
- JSON: https://secwatch.observer/filing/0001104659-25-019462.json
- Plain text: https://secwatch.observer/filing/0001104659-25-019462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.